Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a commercial-stage biopharmaceutical company that develops and sells small-molecule drugs targeting hematologic disorders and cancer. Revenue comes from product sales of its approved drugs, recorded net of rebates, chargebacks, distribution fees, and other deductions. As of December 31, 2025, Rigel had recorded net liabilities for product sales allowances and discounts of $27.7 million, reflecting the managed-care and government rebate obligations typical of specialty pharma. The company is headquartered in South San Francisco, California. Its lead commercial product is TAVALISSE (fostamatinib), a SYK inhibitor with U.S. composition-of-matter patent protection extended to September 2031. Its second commercial product is REZLIDHIA (olutasidenib), an IDH1 inhibitor. Rigel also has a RIPK1 inhibitor program in clinical development partnered with Eli Lilly, and strategic development collaborations with MD Anderson Cancer Center (MDACC) and CONNECT for olutasidenib. CEO Raul R. Rodriguez and CFO Dean L. Schorno signed the 10-K filed March 3, 2026.

Revenue model

Product sales of prescription pharmaceuticals, recorded net of government-mandated and privately-negotiated rebates, chargebacks, distribution fees, estimated returns, and other deductions. The company also has partnership and collaboration arrangements, including a development collaboration with Eli Lilly for its RIPK1 inhibitor program.

Products and services

TAVALISSE (fostamatinib): oral SYK inhibitor approved for hematologic use; U.S. composition-of-matter patent extended to September 2031, with additional Orange Book patents expiring between 2026 and 2032, and pending applications with potential expiration to 2046. REZLIDHIA (olutasidenib): IDH1 inhibitor in commercial use and under further development evaluation for additional IDH1-mutant disease areas. RIPK1 inhibitor: clinical-stage asset partnered with Eli Lilly.

Customers and end markets

Specialty pharmaceutical end markets including hematology and oncology. Patients with immune thrombocytopenia and IDH1-mutant cancers are the primary end users. Payors include government programs (subject to mandatory rebates) and private insurers. The filing does not disclose individual customer concentration data.

Value-chain role

Drug developer and commercial-stage specialty pharma company. Rigel conducts its own commercial operations for approved products in the U.S. while relying on contract research organizations (CROs) and third-party vendors for clinical and operational support. It out-licenses certain pipeline assets to partners such as Eli Lilly.

Geographic exposure

Primary commercial operations in the United States. Fostamatinib has patent protection in Europe and Japan, with composition-of-matter patents extended to 2031 in both regions through supplemental protection certificates and patent term extension. The filing references EU regulatory and data privacy obligations, indicating some international operational presence.

Source: SEC 10-K, filed 2026-03-03

Industry: Pharmaceutical Preparations Peers: 89bio, Inc. Evelo Biosciences, Inc. Kronos Bio, Inc. LianBio MacroGenics Inc Shuttle Pharmaceuticals Holdings Inc Viking Therapeutics Inc Voyager Therapeutics Inc